The emergence of genetic engineering at the beginning of the 1970′ s opened the era of
biomedical technologies, which aims to improve human health using genetic manipulation …

With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic
defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the …

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene that encodes a cAMP …

Cystic fibrosis (CF) is a life-threatening autosomal-recessive disease caused by mutations in
a single gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). CF …

We have recently shown that non-viral gene therapy can stabilise the decline of lung
function in patients with cystic fibrosis (CF). However, the effect was modest, and more …

Cystic fibrosis (CF) is a multiorgan recessive genetic disease caused by mutations in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene. Gene therapy efforts …

The cystic fibrosis transmembrane conductance regulator (CFTR) gene was identified in
1989. This opened the door for the development of cystic fibrosis (CF) gene therapy, which …

Cystic Fibrosis (CF) is an autosomal recessive disease caused by mutations in CF
transmembrane conductance regulator (CFTR), resulting in defective anion transport …

Abstract Knowledge of genetic origins of obstructive lung diseases has made inhaled gene
therapy an attractive alternative to the current standards of care that are limited to managing …

Pulmonary surfactant is critically important to prevent atelectasis by lowering the surface
tension of the alveolar lining liquid. While respiratory distress syndrome (RDS) is common in …